&w=3840&q=100)
Q1 earnings, US Fed decision to drive market sentiments this week: Analysts
Macroeconomic data announcements, monthly auto sales numbers and global market trends would also guide movement in the domestic equities, they said.
Markets would also keep a track on developments related to the August 1 trade deal deadline and geopolitical tensions between Thailand and Cambodia.
August 1 marks the end of the suspension period of Trump tariffs imposed on dozens of countries, including India.
"The start of the new month will bring attention to key economic data, including Industrial Production (IIP) and HSBC Manufacturing PMI on August 1. Additionally, monthly auto sales figures will be closely monitored. The scheduled expiry of the July derivatives contracts may add further volatility to the markets," Ajit Mishra SVP, Research, Religare Broking Ltd, said.
As the earnings season progresses, results from heavyweights such as IndusInd Bank, Asian Paints, NTPC, Tata Steel, Hindustan Unilever, Mahindra & Mahindra, Maruti Suzuki, Sun Pharma, ITC, and others will be tracked for insights on sectoral resilience and corporate performance, he said.
Globally, traders will focus on the US Fed's interest rate decision and GDP growth numbers, along with updates on trade negotiations ahead of Trump's August 1 tariff deadline, which could impact FII flows, Mishra added.
Movement of rupee against the dollar and crude oil prices will also be monitored by investors.
"Looking ahead, all eyes are now on the upcoming Q1 earnings reports from several key companies. Major names like Bharat Electronics Ltd, IndusInd Bank, Asian Paints, Tata Steel, Mahindra & Mahindra, Coal India, Hindustan Unilever, Maruti Suzuki and ITC are set to announce their results this week. Their performance will be crucial in determining whether markets can find support or continue to trend lower in the near term," Pravesh Gour, Senior Technical Analyst, Swastika Investmart Ltd, said.
Investors will closely monitor foreign fund flows, and any meaningful development on the IndiaUS trade front for further direction, he added.
Last week, the BSE benchmark gauge declined 294.64 points or 0.36 per cent, and the Nifty dipped 131.4 points or 0.52 per cent.
"The Indian stock market continued its downward trajectory for the fourth consecutive week, marking the longest losing streak for the Nifty since October 2024. Investor sentiment remained weak, primarily due to the absence of strong domestic triggers, tepid corporate earnings for the June quarter, and persistent selling by foreign institutional investors (FIIs)," Gour said.
Siddhartha Khemka, Head - Research, Wealth Management, Motilal Oswal Financial Services Ltd, said, we expect markets to remain in consolidation mode amid continued uncertainty around India-US trade deal, a mixed Q1 FY26 earnings season so far and intensifying FII outflows.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
25 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hans India
27 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.
Indian Express
27 minutes ago
- Indian Express
Donald Trump eyes new Fed Chair as he calls for Jerome Powell's ouster
US President Donald Trump appears ready to push Federal Reserve Chair Jerome Powell out. The President, who has for months attacked the Federal Reserve Chair as 'stubborn,' signalled Tuesday that he is weighing a list of candidates to succeed Powell and may act soon. 'I didn't say I'm making a decision right now,' he told CNBC. But for anyone watching, the intent was clear: Trump wants Powell gone. Trump has long accused the central bank chief of refusing to lower interest rates in the face of economic slowdown and his own trade war. On Friday, after another disappointing jobs report, he went further, calling on the Fed's board of governors to override Powell. 'THE BOARD SHOULD ASSUME CONTROL,' Trump wrote on Truth Social, 'AND DO WHAT EVERYONE KNOWS HAS TO BE DONE!' The President's frustrations have coincided with a string of economic data that has not gone his way. Friday's nonfarm payrolls report showed just 73,000 jobs added in July – far below expectations – and included downward revisions of 258,000 for the previous two months. Hours later, Trump fired Erika McEntarfer, the commissioner of the Bureau of Labor Statistics, blaming her for 'the biggest miscalculations in over 50 years.' The move stunned economists. 'The risk of politicising the data collection process should not be overlooked,' warned Michael Feroli, JPMorgan Chase's chief US economist. 'Having a flawed instrument panel can be just as dangerous as having an obediently partisan pilot.' But if Trump is steering, he's also reshaping the cockpit. The resignation of Federal Reserve Governor Adriana Kugler, announced Friday, gives Trump a new opening. Kugler's term was set to run until January, but her early departure, combined with McEntarfer's firing, leaves Trump with two powerful vacancies to fill. And he's made it clear he knows the stakes. The Kugler vacancy, wrote Krishna Guha of Evercore ISI, 'jump-starts the Trumpification of the Fed by handing President Trump a vacancy into which he can place a potential or even a clearly designated successor to Powell as Fed chair.' Trump has hinted as much himself—saying his nominee for Kugler's post could well be the next chair when Powell's term expires in May 2026. He's also floated the possibility of pushing Powell out sooner, a move that would draw legal and political fire but has not been ruled out. Trump also ruled out Treasury Secretary Scott Bessent—'He's doing a great job, and he wants to do what he's doing'—but said he is evaluating 'Kevin and Kevin,' referring to former Fed Governor Kevin Warsh and National Economic Council Director Kevin Hassett. 'Both Kevins are very good,' Trump said. Two sitting Fed governors, Christopher Waller and Michelle Bowman, have already broken with Powell on interest rate policy. After Friday's meeting, both issued statements pushing for rate cuts and arguing that Trump's tariffs had only a one-time effect on inflation. Yet the Fed has held interest rates steady through 2025, and Powell has so far resisted Trump's repeated public pressure. The next chance for a rate cut comes in September.
